Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study.

The hedgehog (Hh) pathway is activated in BCR-ABL1 + leukemic stem cells (LSCs) and differentiated hematopoietic cells, through a mechanism involving membrane protein smoothened (SMO) upregulation ...